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HIGHLIGHTS
MINI-REVIEW
A novel “complement–metabolism–inflammasome
axis” as a key regulator of immune cell effector function
Giuseppina Arbore1 and Claudia Kemper1,2
1 MRC Centre for Transplantation, Division of Transplant Immunology and Mucosal Biology,
King’s College London, London, UK
2 Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung, and
Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, USA
The inflammasomes are intracellular multiprotein complexes that induce and regulate
the generation of the key pro-inflammatory cytokines IL-1β and IL-18 in response to
infectious microbes and cellular stress. The activation of inflammasomes involves sev-
eral upstream signals including classic pattern or danger recognition systems such as the
TLRs. Recently, however, the activation of complement receptors, such as the anaphyla-
toxin C3a and C5a receptors and the complement regulator CD46, in conjunction with the
sensing of cell metabolic changes, for instance increased amino acid influx and glycol-
ysis (via mTORC1), have emerged as additional critical activators of the inflammasome.
This review summarizes recent advances in our knowledge about complement-mediated
inflammasome activation, with a specific focus on a novel “complement – metabolism –
NLRP3 inflammasome axis.”
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Introduction
The immune system constantly orchestrates a range of effec-
tor pathways to handle the detection and elimination of not
only exogenous microbes but also endogenous dangerous enti-
ties, such as infected, apoptotic or malignant cells. Microbe-
derived molecules, known as pathogen-associated molecular pat-
terns (PAMPs) and noxious self-derivedmolecules, named danger-
associated molecular patterns (DAMPs), are recognized by dif-
ferent pattern recognition receptors (PRRs) expressed on or
secreted by immune cells. Among these ‘systems’ comprising clas-
sic PRRs, are the toll-like receptors (TLRs), the Nod-like recep-
tors (NLRs) and the retinoic acid inducible gene 1 (RIG-I) recep-
tors, and several proteins of the complement system (reviewed
in [1, 2]). The engagement of these PRRs leads to cell acti-
vation and induction of appropriate protective effector func-
tions specific for the cells that receive these signals. One of
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the most critical effector functions of the PRRs is to induce
assembly and activation of “inflammasomes.” Inflammasomes are
multiprotein complexes, which are required for the induction and
maturation of the key host proinflammatory cytokines IL-18 and
IL-1β. In particular, the engagement of TLRs, NLRs, and RIG-Is
have been demonstrated to activate the inflammasomes via a series
of different downstream pathways (reviewed in [1, 3]).
Recent work, however, demonstrates that activation of the
complement system and subsequent engagement of complement
receptors and regulators on immune cells, either independently or
in conjunction with incoming signals from TLRs or RIG-Is, are also
vital signals for the activation and optimal function of inflamma-
somes [4, 5]. Given that the complement system is evolutionarily
among the oldest PRR systems [2], and that extensive cross-talk
between complement and particularly the TLRs exists [2, 6], the
involvement of complement in inflammasome activation is not
unexpected. What comes as a surprise, however, is that the com-
plement system emerges as central regulator of basic metabolic
processes of the cell and that a novel “complement—metabolism–
inflammasome axis” may be contributing to optimal effector func-
tion of immune cells during inflammation.
C© 2016 The Authors. European Journal of Immunology published by WILEY-VCH Verlag GmbH & Co.
KGaA, Weinheim.
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In addition to specific danger sensors such as the PRRs, both
innate and adaptive immune responses are also modulated by a
series of metabolic checkpoint systems. For example, quiescent
cell subsets, such as nonactivated and circulating myeloid and
lymphoid cells, rely on mitochondrial oxidative phosphorylation
(OXPHOS) via the tricarboxylic acid cycle and beta-oxidation of
fatty acids, as their main energetic fuel [7–9]. Conversely, acti-
vation of such cells and induction of effector function requires,
in most cases, increased glycolysis to supply the elevated energy
demand for proliferation, induction of cytokine secretion, phago-
cytosis etc. [7–9]. Importantly, these metabolic changes, including
increased glycolysis, mitochondrial stress, and membrane elec-
trolyte fluxes, are sensed within the cell and have been shown to
subsequently activate and/ormodulate particularly NLRP3 inflam-
masome functions [3, 10–12]. Conversely, it has been demon-
strated that several complement receptor/regulators drive the reg-
ulation of nutrient channel expression and influx of amino acids
(AAs) and glucose, as well as direct regulation of glycolysis and
OXPHOS levels (at minimum in CD4+ T cells) [13], and com-
plement is now increasingly being connected with the metabolic
reprogramming required for immune cell effector function. In this
short review, we will discuss insights into the emerging novel
functional relationships between the complement system, key cell
metabolic pathways, and inflammasome activation and function.
The inflammasome
Upon specific induction signals, including exogenous antigens
derived from invading microbes or endogenous ligands gener-
ated during cell activation and/or stress [1, 3], several members
of the NLR protein family, the Pyrin domains-containing pro-
tein (NLRP) family and the Pyrin and HIN domain containing
(PYHIN) family form multiprotein complexes known as “inflam-
masomes,” whose structure and functions are conserved in ver-
tebrate species [14]. Members of the NLR protein family include
NAIP (neuronal apoptosis inhibitor protein), C2TA (class 2 tran-
scription activator, of the MHC), HET-E (heterokaryon incom-
patibility) and TP1 (telomerase-associated protein 1), leucine-
rich repeats, and Pyrin domains-containing protein 1 (NLRP1),
NLRP3, NLRP6 as well as NLR family CARD (caspase activation
and recruitment) domain containing 4 (NLRC4), and members
of the PYHIN family include absence in melanoma 2 (AIM2)
and IFN-γ inducible protein 16 (IFI16) [3, 15, 16]. These dif-
ferent inflammasomes all respond to different danger signals
(reviewed in [3, 15]). Currently, the best-characterized inflam-
masome both in humans and mice is the NLRP3 inflammasome
complex, which is composed of NLRP3 (known also as cryopy-
rin, NALP3, CIAS1, or PYPAF1), the adaptor apoptosis speck pro-
tein (ASC), and procaspase-1 [17]. NLRP3, as shown for other
NLRs, is present in the cytoplasm in an inactive form associated
with the heat shock protein 90 (HSP90) and the ubiquitin-ligase
suppressor of the G2 allele of skp1 (SGT1) [18]. Sensing of spe-
cific molecules, such as bacterial peptidoglycans or the bacterial
cell wall component LPS by TLR4 or monosodium urate parti-
cles, induce inflammasome activation: specifically, HSP90 and
SGT1 release NLRP3, which then binds the Pyrin domain of ASC,
leading to procaspase-1 binding to the ASC CARD domain, via
CARD–CARD homotypic interactions [3, 15, 16, 18]. This binding
cascade triggers the formation of oligomers (speck complexes)
of many molecules of NLRP3, ASC, and procaspase-1, with this
active complex then releasing the functional “end product,” the
active p20 and p10 caspase-1 fragments [1, 15]. Noncanonical
NLRP3 inflammasome activation (which is independent from sur-
face TLR4 engagement by LPS, but triggered instead by cytoso-
lic sensing of LPS derived from bacteria that have escaped the
phagolysosome) can also occur either via caspases-4/5 [19, 20],
caspase-8 [21], and caspase-11-mediated assembly of the NLRP3
inflammasome complex [22]. However, there is currently no
known functional connection between complement and caspase
activation, and the focus in this review will thus be on the func-
tional connection between complement and canonical inflamma-
some activation. The main function of NLRP3 inflammasome-
driven caspase-1 activation is the subsequent conversion of inac-
tive proIL-1β and proIL-18 into their active and secreted forms [3].
IL-1β and IL-18 are proinflammatory cytokines and required for
protective innate and adaptive immune responses. IL-1β and IL-
18 are mostly produced by monocytes, macrophages, APCs, and
neutrophils, and enhance the effector function of these cells dur-
ing pathogen clearance (reviewed in [23]). Furthermore, it has
been shown that IL-1β supports T-cell priming and Th1 and Th17
responses in humans [24, 25] and memory T-cell generation in
mice [26], while IL-18 enhances IFN-γ production by NK cell T
lymphocytes, as demonstrated in mouse studies [27].
NLRP3 inflammasome function has been described both in
human and in mice in myeloid innate immune cells, with mono-
cytes as the main source of IL-1β [25, 28], and in several non-
immune cell types (such as microglia, endothelial, and retinal
pigment epithelial cells) in both species [29–31].
Although the generation of IL-1β is critical to combat invading
pathogens, uncontrolled inflammasome activation has also been
demonstrated to contribute to the development of pathogenic
(auto) inflammatory diseases, including type 1 diabetes and
rheumatoid arthritis (RA) [32, 33]. For example, gain-of-function
mutations in NLRP3 are associated with a group of herita-
ble monogenic syndromes known as cryopyrin-associated peri-
odic syndromes (CAPS), characterized by excessive production of
IL-1β from APCs with recurrent fevers, skin rashes, joint and ocu-
lar inflammation, and amyloidosis in patients [34]. Therapeutic
suppression of the unwanted inflammatory responses in CAPS
patients can be achieved by IL-1R blockade with the IL-1 recep-
tor antagonist anakinra, or canakinumab, a monoclonal antibody
targeting IL-1R1 [34, 35]. Thus, NLRP3-driven IL-1β secretion is
tightly regulated and requires, at minimum, two “danger” signals:
Signal 1 is a priming signal and is initiated by the engagement
of other PRRs, including TLR4 or by cytokine receptors, such as
the tumor necrosis factor receptor, which then promote nuclear
translocation of nuclear factor κB (NF-kB), leading to gene tran-
scription and translation of NLRP3 and IL1B [36]. Several exoge-
nous or endogenous molecules can deliver Signal 2, which induces
C© 2016 The Authors. European Journal of Immunology published by
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NLRP3 assembly and formation of ASC speck aggregates. Exoge-
nous signals inducing NLRP3 assembly include microbial, fun-
gal, viral, and parasitic products such as toxins and glycans and
environmental polluters such as silica and asbestos [3, 37–39]
and disease-associated accumulation of altered protein com-
plexes, such as cholesterol crystals in atherosclerosis, amyloid β
in Alzheimer disease and monosodium urate in gout [3, 5, 29].
Endogenous sources of Signal 2 include products of events occur-
ring during cell activation, including reactive oxygen species
(ROS), cathepsins B and L released during lysosomal dam-
age, increased cytoplasmic Ca2+ as a product of ion fluxes (K+
efflux), altered adenosine triphosphate (ATP) production or ATP
influx via the ATP receptor P2X purinoceptor 7 (P2X7), and
changes in, glucose and lipid metabolism [ 3, 10–12, [40]].
The common denominator among the endogenous signals driving
NLRP3 inflammasosme activation is that they are all derived from
metabolic changes accompanying cell (hyper) activation. Thus,
NLRP3 appears to be a major sensor for cell metabolic activity
and stress, and this is underscored by the recent observations
that dysregulation of the NLRP3 inflammasome contributes also
to metabolic diseases and pathologies, such as gout, type 2 dia-
betes (T2D), nonalcoholic fatty liver disease, obesity, and cancer
(reviewed in [34]).
There are several excellent reviews published on these new
pathways driving NLRP3 inflammasome activation and function
for further in-depth reading [41, 42].
The complement system
The complement system was originally defined over a century
ago by Paul Ehrlich as a “system” of serum-circulating proteins
able to “complement” the antibody-mediated and cell-mediated
immune responses [43]. Complement is a critical part of innate
immunity and a major initiator of the inflammatory reaction. It
is comprised of over 50 blood-circulating, mostly liver-derived,
and membrane-bound proteins and regulators with the effector
molecules existing largely in a precursor state that is activated
rapidly in a cascade-like fashion following activation of the sys-
tem [44]. Three pathways lead to complement activation in blood:
the classical, the lectin, and the alternative pathway (reviewed
in [44]) and all pathways are triggered when complement sen-
tinel proteins, such as the mannose-binding lectin (MBL) and
C1q [45, 46] sense the presence of microbes. Importantly, and
similar to TLRs and the inflammasomes, complement-derived sen-
sors recognize both PAMPs but also DAMPS. For example, MBL
binds to specific carbohydrates only present on pathogens such
as mannose [45], while ficolins and the C1 complex (C1q) detect
danger molecules produced by stressed and dying cells, such as
surface blebs on apoptotic human keratinocytes [46]. Although
triggered by different signals, all activated pathways—the classi-
cal, the lectin, and the alternative—cumulate into the generation
of a “so-called” C3 convertase, a protein complex that cleaves the
key complement effector molecule C3 into the bioactive opsonin
C3b and the anaphylatoxin C3a. The subsequent generation of C5
convertases activates C5 into C5b (which seeds the generation of
the pore-forming membrane attack complex (MAC)) and the ana-
phylatoxin C5a [44]. Functionally, the activation of complement
leads to the opsonization of targets (via C3b), the migration and
activation of innate immune cells (via the receptors for the ana-
phylatoxins C3a and C5a) and direct lysis (via the MAC) and/or
phagocytic uptake of the target pathogen by scavenger cells (via
engagement of C3 activation fragment receptors) [47].
Aside from the mobilization of innate immune cells and
induction of the general inflammatory reaction, complement also
directly modulates adaptive immunity [44]. Engagement of com-
plement receptor 2 (CR2, CD21) through C3d-coated antigen
during BCR activation in the lymph nodes has been shown to
reduce the threshold for BCR signaling, and is needed for opti-
mal antibody production in mice [48]. Also, macrophages capture
immune complexes that are recognized by follicular B cells in the
subcapsular sinus via CR2 [48, 49], and, in addition, immune
complexes coated with C3 activation fragments are recognized by
follicular dendritic cells, which retain the antigen, thus enhanc-
ing B-cell memory and effector differentiation in the germinal
centers [50]. Complement activation products also impact on
T-cell activation and regulation, either indirectly by influencing
the maturation and function of APCs, or directly by engaging
complement receptors/regulators expressed on T cells [51]. For
example, concurrent signaling by the C3b/C4b-binding comple-
ment regulator CD46 (membrane cofactor protein, MCP) and
the C3aR expressed on CD4+ T cells has been proved to be
a prerequisite for IFN-γ production and human Th1-cell induc-
tion [52–54], and dysregulation of CD46-mediated costimula-
tory signals on T cells has been identified in chronic disease set-
tings, including multiple sclerosis [55] and RA [52]. Moreover,
in mice (which do not express CD46 on somatic tissue [44]), the
anaphylatoxin receptors are shown to be critical for the induc-
tion and regulation of Th1, Th2, Th17, and natural Treg-cell
responses [56, 57].
Specifically, the recent work on the function of complement
receptors and regulators on human CD4+ T cells has led to two
important new discoveries: First, immune cells produce comple-
ment C3 and C5 activation fragments that in turn engage cell-
expressed complement receptors in an autocrine fashion (thus,
providing signals independent of liver-derived serum-circulating
complement) [51, 54, 57] and, second, complement activation is
not confined to the extracellular space but occurs intracellularly
[52, 54, 58]. Importantly, engagement of intracellular comple-
ment receptors, such as C3aR, induces signaling pathways that
are distinct from those induced by the same complement recep-
tors expressed on the cells surface [44, 54]. Specifically, C3 acti-
vation occurs intracellularly via cathepsin L-mediated cleavage
of C3 in human CD4+ T cells, and the C3a generated via this
“pathway” has been shown to stimulate intracellular C3aR signal-
ing on lysosomes; this intracellular C3aR signaling in turn drives
the homeostatic survival of resting T cells via tonic mammalian
target of rapamycin (mTOR) stimulation [54]. During TCR activa-
tion in human T lymphocytes, C3a and C3b generated intracellu-
larly rapidly translocate to the cell surface where they engage cell
C© 2016 The Authors. European Journal of Immunology published by
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surface C3aR and CD46, respectively, both of which are events
driving productive IFN-γ secretion [13, 54]. In addition, experi-
mental observations demonstrate that intracellular C3 activation
by cathepsin L is dysregulated in T cells from patients with RA,
and contributes to Th1 hyperactivity, but can be normalized via a
cell-permeable cathepsin L inhibitor [54].
A more detailed description of extra- and intracellular comple-
ment activation, regulation, and function in mice and humans are
thoroughly reviewed in [44].
Complement in the activation and regulation of the
NLRP3 inflammasome
Given that the complement system and the NLRP3 inflammasome
share a “mutual interest” in protecting the host against danger,
a functional cross-talk between these two systems feels natu-
ral (Fig. 1). Indeed, studies in the 1980s by Haeffner-Cavallion
et al. showed that the anaphylatoxin C3a induces IL-1β produc-
tion in human monocytes [59], indicating a functional connection
between these two systems at a time before the inflammasome
was actually discovered. A more recent study defined the C3aR-
driven signals in human monocytes and demonstrated that locally
produced C3a increases ATP efflux from the monocyte cytosol
(via ERK1/ERK2 phosphorylation and expression regulation of a
yet-unidentified channel) in the presence of TLR4 activation by
LPS [4]. This C3a-driven ATP efflux leads to subsequent increased
activation of the ATP receptor P2X7, a potent Signal 2 for NLRP3
inflammasome activation [37], and substantially increased IL-1β
secretion [4] (Fig. 1). Furthermore, the anaphylatoxin C5a has
been confirmed as an important driver of Signal 1 for NLRP3
inflammasome activation in human monocytes: Samstad et al. [5]
showed that cholesterol crystals activate both the classical (via
C1q) and alternative complement pathways and that C5a gen-
erated during this process, together with TNF-α, functions as
priming Signal 1 for NLRP3 activation by increasing IL1B gene
transcription (Fig. 1). Work by the same group has determined
that high-density lipoprotein reduces complement activation on
cholesterol crystals and leads to a reduction in NLRP3 inflamma-
some activity in monocytes and granulocytes during atherosclero-
sis [60]. C5aR-mediated signals may regulate IL1B transcription
via NF-κB activation because locally increased C5a levels have
been shown to induce NF-κB activation in retinal pigment epithe-
lial cells and trigger IL-18 secretion from these cells [31]. In mouse
retinal epithelial cells, C1q also increases NLRP3 inflammasome-
dependent IL-18 production (which protects unexpectedly against
the progression of age-related macular degeneration) in mice,
however, the exact mechanism but which this occurs remains to
be identified [61]. There is also indication that CD46 partakes
in NLRP3 inflammasome priming, as CD46 engagement during
TCR stimulation on human CD4+ T cells potentiates NF-kB acti-
vation [13] and increases transcription of IL1B [58]. C5a activa-
tion can also increase inflammasome activation in models of gout
disease: C5aR1 activation on monocytes, primes, and potentiates
NLRP3 inflammasome activation induced by uric acid crystals,
with the latter being dependent on lysosomal damage and cathep-
sin B activity [62] (Fig. 1); this role for C5a as has been further
corroborated in neutrophils in a mouse peritonitis model and in
human gout exudates from the articular joints [63].
One of the other major routes by which C5a (and possibly C3a)
may regulate NLRP3 inflammasome activity is likely via increased
generation of ROS [5, 58]. ROS not only constitutes a general
danger Signal 2 for inflammasome activation [15, 64], but has
traditionally also been linked tightly with anaphylatoxin recep-
tor activation in APCs, neutrophils, and granulocytes [5, 65, 66].
Furthermore, C5aR1 activation involves PI3 kinase signaling [56],
which has been placed upstream of mitochondrial ROS production
and NLRP3 inflammasome activation [67] (Fig. 1).
In line with the fact that pore forming toxins are strong inflam-
masome inducers [37], sublytic deposition of the MAC has been
demonstrated to activate the NLRP3 inflammasome inmurine den-
dritic cells and elicits IL-1β and IL-18 secretion in a caspase-1-
dependent fashion [68]. Similarly, in primary human lung epithe-
lial cells, sublytic MAC induces the NLRP3 inflammasome via
increased intracellular Ca2+ fluxes from the endoplasmic retic-
ulum, Ca2+ accumulation in the mitochondrial matrix and loss of
mitochondrial transmembrane potential (Signal 2) that triggers
the NLRP3 inflammasome [69, 70] (Fig. 1).
Aligning with the understanding that the complement sys-
tem is involved in both initiation and contraction of immune
responses [71], complement has also been shown to negatively
regulate NLRP3 inflammasome activity: C1q suppresses caspase-
1 cleavage and subsequent mature IL-1β production in human
monocyte-derived macrophages during the phagocytosis of apop-
totic lymphocytes [72]. The authors suggest that C1q may drive
NLRP12 mRNA expression and IL-10 secretion, as both NLRP12
(via NF-kB suppression) and IL-10 (through activation of JAK sig-
naling) are known to negatively regulate the NLRP3 inflamma-
some [73, 74] (Fig. 1). Thus by directly regulating NLRP3 inflam-
masome activation, C1q may limit the excessive NLRP3 inflam-
masome activation triggered by DAMPs (Fig. 1) released by late
apoptotic cells [72]. Given the merging role of C1q in inflamma-
some regulation, It may therefore be worthy to revisit the role of
defective C1q activity observed in autoimmune disease such as in
systemic lupus erythematosus [46] with an eye on this new C1q
function.
Cell metabolism as critical link between complement
and NLRP3 inflammasome activation
Although complement, the TLRs, and the inflammasomes were ini-
tially discovered as pathogen sensors, it is now becoming increas-
ingly clear that the ability of these systems to recognize an imbal-
ance in normal cell metabolic processes and their capability to
evoke appropriate reactive responses is of equal importance to
cell homeostasis. For example, NLRP3 inflammasome priming and
activation are strongly driven by increased glucose influx, height-
ened glycolysis, and increased ATP production, as demonstrated
in human retinal tubular epithelial cells in diabetic nephrophaty
C© 2016 The Authors. European Journal of Immunology published by
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Figure 1. Mechanisms of complement-mediated NLRP3-inflammasome regulation. NLRP3 inflammasome activation requires two distinct signals.
The “priming” Signal 1 is triggered by PAMP/DAMP recognition by PPRs (e.g. TLRs) and certain cytokines (TNF-α) and drives NF-κB nuclear
translocation and NLRP3 and IL1B gene transcription. Signal 2 induces the assembly of NLRP3, ASC, and caspase-1 supracomplexes to form
an active NLRP3 inflammasome, where active caspase-1 processes proIL-1β/proIL-18 into mature IL-1β/IL-18. The complement components C1q
and C5aR1 (together with tumor necrosis factor receptor and/or TLR signaling) potentiate Signal 1. C5aR1 act as a priming signal to sustain
inflammasome activation during the uptake of DAMPs, with a mechanism involving increased lysosomal damage and cathepsin B release. C5aR1
activation directly delivers Signal 2 for NLRP3 inflammasome activation, via induction of mitochondrial damage and intracellular accumulation
of ROS. The C3aR regulates ATP efflux (via a not yet identified channel, denoted by a question mark) and subsequent autocrine P2X7 engagement,
and sublytic MAC formation increases intracellular Ca2+ levels andmitochondrial membrane potential. Of note, C1q can increase canonical NLRP3
inflammasome activation in epithelial cells through a not yet definedmechanism (denoted by a question mark) but can also function as a negative
regulator of NLRP3 inflammasome activation by sequestering DAMPs (such as cholesterol crystals) and inhibiting PPR signaling.
[75], all events generally required for cell activation, proliferation,
and effector function [8]. Furthermore, both enzymes and prod-
ucts of glycolysis and the Krebs cycle have been shown to regu-
late NLRP3 inflammasome activity: the glycolytic enzyme pyruvate
kinase M2 drives LPS-induced NLRP3 activation in macrophages
by regulating the hypoxia-inducible factor 1 (HIF-1α), a
transcription factor that binds directly to the IL1B promoter and
causes sustained production of this cytokine [76]; and the Krebs
cycle product succinate stabilizes HIF-1α further, thereby support-
ing IL1B transcription [77]. As a major glycolysis product, ATP is
a strong driver of NLRP3 inflammasome assembly, as it activates
P2X7 and induces IL-1β and IL-18 maturation and release [78].
Also, adenosine itself sustains inflammasome activation induced
by LPS, through stimulating the adenosine A(2A) receptor and
cAMP/PKA/CREB/HIF-1α pathway, a priming signal for IL-1β pro-
duction [79].
The NLRP3 inflammasome also integrates signals derived
from AA and lipid metabolism in cells as well as ROS produc-
tion, which is increased upon heightened mitochondrial activity
required for cell effector functions. Activation of the AA sensor
mammalian target of rapamycin complex 1 (mTORC1) has been
demonstrated to be a potent NLRP3 inflammasome inducer in
macrophages [80]. Moreover, using the human monocytic cell
line THP-1, active NLRP3 inflammasomes have been shown to
colocalize with mitochondria [11], where increased ROS gen-
erated by mitochondrial activity sustains NLRP3 inflammasome
function [64].
Metabolic by-products can also inhibit NLRP3 inflamma-
some activation. In particular, increased AMP generation acti-
vates the nutrient sensor AMP-dependent protein kinase (AMPK)
that impacts negatively on NLRP3 inflammasome function, as
AMPK signaling promotes the switch from energy-consuming
processes such as glycolysis (which generally denotes states of
high cellular activity) to oxidative metabolism associated with
anti-inflammatory and quiescent states and favors mitochondrial
biogenesis and reduction in NLRP3 activation [41, 81, 82]. Simi-
C© 2016 The Authors. European Journal of Immunology published by
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larly, increased lactate, themain product of anaerobic glycolysis, is
associated with reduced TLR4-mediated inflammasome induction
in monocytes and macrophages, through a pathway dependent on
the lactate receptor Gi-protein-coupled receptor 81 and arrestin β-
2 [83]. The ketogenic metabolites β-hydroxybutyrate [84], mono-
unsatured fatty acids (through AMPK signaling) [85], the N-
methyl-d-aspartate receptor for poly-unsaturated fatty acids [86]
and prostaglandin E2 [87] have all been shown to inhibit inflam-
masome activity. Thus, the metabolic state of a cell modulates
NLRP3 inflammasome function andmetabolites produced by a cell
during effector activity induce the inflammasome, while metabo-
lites produced during quiescent, contracting, or tolerogenic cell
responses inhibit inflammasome activity. Importantly, inflamma-
somes may not only integrate intracellular signals but also sense
metabolic dysregulation on a systemic level, as the higher con-
centration of blood glucose found in T2D has been associated
with NLRP3 inflammasome activation and high serum IL-1β in
patients [64].
Although it is long known that systemic complement activa-
tion impacts on the function of metabolic organs (for an excellent
review please see [88]), autocrine complement activity can now
also be connected with the regulation of “single cell” metabolism
driving cell activation. For example, CD46 costimulation during
T-cell stimulation is required for metabolic reprogramming dur-
ing Th1-cell responses [13]. CD46 is expressed in distinct iso-
forms (arising from differential splicing of a single gene) in CD4+
T cells and these isoforms differ in the expression of their cyto-
plasmic tails, termed CYT-1 and CYT-2. Both domains can trans-
duce intracellular signals [52, 53, 71] and resting T cells mostly
express CD46-CYT-2 [13, 52, 53] (Fig. 2). Upon TCR stimula-
tion, CYT-1-bearing CD46 isoforms are upregulated, engaged via
T-cell autocrine C3b production and induce the increased expres-
sion of the glucose and AA channels, GLUT1 and LAT1, respec-
tively, thereby mediating the nutrient influx needed for T-cell
activation (Fig. 2). Moreover, CD46-CYT-1 also upregulates the
late endosomal/lysosomal adaptor, MAPK and MTOR activator 5
(LAMTOR5), which then drives mTORC1 assembly and activation
with subsequent increased glycolysis (Fig. 2) [13], in line with pre-
vious work that has linked augmented glycolysis in human CD4+
T cells with IFN-γ production [89]. CD46-mediated signals also
induce the switch from a high glycolytic state back to steady-state
glycolysis levels in CD4+ T cells and, via this, subsequently IL-10
coproduction and finally Th1 contraction [13] (Fig. 2). This switch
from high to low glycolysis is mediated by CD46 isoforms express-
ing CYT-2, which become again the predominant CD46 isoforms in
contracting T cells [13]. The mechanism regulating CD46 isoform
splicing or switching is not defined yet. Interestingly, CD46-CYT-1
also increases OXPHOS levels in activated T cells [13] and we
are currently investigating the underlying CD46-mediated signals
driving this OXPHOS “burst” during T-cell activation and its poten-
tial role in T-cell homeostasis and/or memory development. The
unexpected critical roles for complement and specifically CD46
in CD4+ T-cell metabolic reprogramming is underpinned by the
fact that T cells from CD46-deficient patients have a defect in
glycolysis, OXPHOS and Th1 (and Th17) induction [13]. How-
ever, as a complement regulator serving as the murine homolog
of CD46 in regards to Th1 induction and regulation has so far not
been identified, these findings also show that there are substantial
differences between species in the complement-mediated signal-
ing pathways regulating cell metabolism.
Our recent work now suggests that autocrine comple-
ment activation-driven metabolic changes are direct and critical
upstream activators of the NLRP3 inflammasome in humans: We
have now found that the canonical NLRP3 inflammasome sur-
prisingly assembles not just in myeloid innate immune cells, but
also in human activated CD4+ T cells, where it initiates caspase-
1-dependent IL-1β secretion and promotes IFN-γ production and
Th1 differentiation in an autocrine fashion [58] (Fig. 3). Impor-
tantly, NLRP3 assembly in these activated CD4+ T cells requires
CD46 signaling, which not only induces IL1B gene transcription
but also the increased intracellular generation of C5a and activa-
tion of the C5a receptor 1 (C5aR1). Intracellular C5aR1 engage-
ment subsequently impacts on oxygen metabolism by inducing
strong ROS generation and subsequent NLRP3 inflammasome acti-
vation (Fig. 3). Interestingly, CD46 and C5aR1-driven NLRP3 acti-
vation in human CD4+ T cells induces IL-1β but not IL-18 produc-
tion [58]. This is in contrast to mouse retinal epithelial and den-
dritic cells were complement activation is a strong inflammasome-
dependent inducer of both IL-1β and IL-18 [61] and suggests that
complement-mediated production of these two cytokines is likely
cell and/or context specific.
We also observed that CD46 and C5aR1-driven NLRP3 acti-
vation is negatively controlled by surface-expressed C5aR2 in an
autocrine fashion, either through inhibition of intracellular C5aR1
activity or via a yet undefined mechanism (Fig. 3). We envis-
age that, whereas APC-derived NLRP3-activated IL-1β supports
initial Th1 priming, maintenance of the Th1 phenotype during
differentiation and migration into the periphery may rely on the
autocrine complement/NLRP3 cross-talk. Importantly, we indeed
observed that dysregulation of these autocrine pathways affects
the inflammatory responses in autoimmune disease: CD4+ T cells
from patients with CAPS, who express mutated, constitutively-
active NLRP3, and have increased autocrine IL-1β secretion exhibit
strongly increased Th1 responses that are normalized by treat-
ment with the NLRP3 inflammasome-specific inhibitor MCC950
[58, 90].
Since mTORC1 activity has recently been identified as
an NLRP3 inflammasome activator [80] and HIF-1α stabilizer
[91], we suggest a novel functional “complement-metabolism-
inflammasome axis” in which autocrine complement-mediated
signals from C3 and C5 activation fragments drive NLRP3 and
IL1B transcription (Signal 1, via CD46 and/or C5aR1), but also
provide Signal 2 via increased oxygen metabolism and ROS pro-
duction (C5aR1) and additional induction of metabolic changes
(mTORC1 assembly and glycolysis via CD46), all of which cumu-
late in NLRP3 activation, IL-1β secretion and optimal Th1 induc-
tion (Fig. 3). Aligning with this model, we have observed that
inhibition of mTOR by rapamycin abrogates NLRP3 activation
and IL-1β production in T cells, and reduces Th1-cell induction
(Arbore and Kemper, unpubl. obs.). Thus, the regulated cross-talk
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Figure 2. The role of C3 activation fragments in T-cell homeostasis and in the induction of key metabolic events during Th1 responses. In resting
T cells, the “tonic” generation of intracellular C3a via cathepsin L leads to the activation of the C3aR expressed on lysosomes and the low-level
activation of mTOR that sustains T-cell survival (left). TCR activation and CD28 costimulation of resting T cells induces the local generation
of the CD46 ligand C3b and increased expression of CD46 isoforms bearing CYT-1 (1, middle). Autocrine CD46 CYT-1-driven signals then lead to
upregulation of genes coding for the glucose transporter GLUT (SLC2A1), and the amino acid channel LAT1 (SLC7A5), allowing for increased influx of
glucose and amino acids into the cell (2). In parallel, CD46 CYT-1-mediated signals induce increased expression of LAMTOR5, and via this assembly
of the lysosome-based machinery enabling amino acid sensing via mTORC1, which then leads the induction of glycolysis and OXPHOS required
for IFN-γ production (3). During Th1 contraction and induction of IL-10 coexpression, CD46 isoform expression reverts to a CYT-2 predominant
pattern (through a mechanism that is currently unknown) and this is accompanied by reduced expression of GLUT1 and LAT1, downregulation of
glycolysis and OXPHOS and reinstatement of C3a-driven low level mTOR activity (right).
between intracellularly activated complement components (the
“complosome” [44, 58]), key metabolic pathways and the NLRP3
inflammasome emerges as fundamental to human Th1 induction
and regulation. Although this new functional connection between
these systems has so far only been shown in CD4+ T cells, we
suggest that they also cooperate during cell activation and induc-
tion of effector function in other cells, including monocytes, APCs,
neutrophils etc.
Furthermore, we found that T cells from CAPS patients have
increased intracellular C5 expression and activation (Arbore
et al., unpubl. obs.), which suggests that (intracellular) com-
plement is not only an upstream inducer of NLRP3 inflamma-
some function but is, in turn, also regulated by NLRP3 activity.
Similarly, the NLRP3 inflammsome not only senses metabolic
changes but also contributes to the adaptions in glucose and
triglyceride metabolism required during normal nutrient intake
and energy expenditure (reviewed in [92]). Thus, this novel
complement-metabolism-inflammasome axis described here is
likely part of a complex network in which all three systems engage
in cross-talk that is regulated by an intricate balance of positive
and negative feedback loops. In this regard, it will be interesting to
assess whether the complosome not only drives metabolism but is
also able to sense metabolic changes and contribute to appropriate
cellular adjustments.
Conclusions
Accumulating evidence suggests that ancient pathogen-sensing
systems are also at the heart of “normal” cell activation and home-
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Figure 3. A complement-metabolism-inflammasome axis regulating human Th1 response induction and contraction. TCR stimulation of human
CD4+ T cells induces the autocrine activation of CD46 and the C3aR via the “C3 system” that cumulates in nutrient influx,mTORC1 activation (which
is a NLRP3 inflammasome activator) and induction of key metabolic events (see Fig. 2 for details). In addition, CD46 stimulation simultaneously
induces gene expression ofNLRP3 and IL1B to prime theNLRP3 inflammasome aswell as increased intracellular C5 activation and C5a generation (of
note, the enzyme cleaving intracellular C5 into C5a and C5b has not yet been identified and is denoted by a questionmark). Intracellularly generated
C5a then engages the intracellular C5aR1 to amplify ROS production. Increased ROS levels, together with the indicated metabolic changes, induce
the assembly of the NLRP3 inflammasome and subsequent IL-1β (but not IL-18) production required for optimal Th1-cell induction. Cell surface
expressed C5aR2 (engaged via secreted C5a/C5adesArg) negatively regulates C5aR1 signaling via a yet-unidentified mechanism—and therefore
controls the Th1-cell responses.
ostasis and function via inducing and/or recognizing metabolic
changes—and an emerging novel cross-talk between (intracellu-
lar) complement as unexpected key regulator of cell metabolism
and the NLRP3 inflammasome that senses changes in cellular
metabolic states may be a critical contributor to this surveillance
system. This notion suggests that the role of the complement sys-
tem not only in autoimmune but also inmetabolic diseases (includ-
ing cancer) should be reevaluated—as a better understanding of
the inducing and regulative mechanisms underlying these new
roles for complement may deliver the foundation for novel thera-
peutic strategies combating these diseases.
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